<prompt> Tildrakizumab was approved in March 2018 forPsoriasisHIVRheumatoid ahritisHepatitis C  <response>: Tildrakizumab was designed to block interleukin-23, a cytokine that plays an impoant role in managing the immune system and autoimmune disease. It is approved for the treatment of moderate-to-severe plaque psoriasis.Ref: 